|
4. Commitments and Contingencies (Details Narrative) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 3 Months Ended | |||||
|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
Innovacyn
|
Mar. 31, 2013
Innovacyn
|
Jun. 30, 2013
More Pharma
|
Mar. 31, 2013
More Pharma
|
Jun. 30, 2013
More Pharma
|
|
| Potential Severance of Key Executives | $ 1,918 | ||||||
| Aggregated Annual Salaries of Key Executives | 1,360 | ||||||
| Revenue related to Vetericyn, Inc. and Innovacyn, Inc. agreements | 741 | 1,136 | |||||
| Accounts receivable | 610 | 264 | 847 | 580 | |||
| Amortization of upfront fees recognized in income | 375 | ||||||
| Product licensing fees | 433 | 12 | 433 | ||||
| Other expense, net | $ 28 | $ 20 | $ 16 | ||||
| X | ||||||||||
|
- Definition
Aggregated annual salaries of key executives No definition available.
|
| X | ||||||||||
|
- Definition
Amortization of upfront fees recognized in income No definition available.
|
| X | ||||||||||
|
- Definition
Potential severance of key executives No definition available.
|
| X | ||||||||||
|
- Definition
For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of other expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating expense recognized during the period. Such amounts may include: (a) unusual costs, (b) loss on foreign exchange transactions, (c) losses on securities (net of profits), and (d) miscellaneous other expense items. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|